Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: classes from mouse fashions, implications for people. Blood. 2012;120:5118–27.
Ito Ok, Hirao A, Arai F, Matsuoka S, Takubo Ok, Hamaguchi I, et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature. 2004;431:997–1002.
Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, Dombkowski DM, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006;443:421–6.
Wang J, Solar Q, Morita Y, Jiang H, Gross A, Lechel A, et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA injury. Cell. 2012;148:1001–14.
Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, et al. The affect of altered p53 dosage on hematopoietic stem cell dynamics throughout ageing. Blood. 2007;109:1736–42.
Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4:37–48.
Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 2000;287:1804–8.
Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon Ok, et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010;24:1389–402.
Fiscella M, Zhang H, Fan S, Sakaguchi Ok, Shen S, Mercer W. Wip1, a novel human protein phosphatase that’s induced in response to ionizing radiation in a p53-dependent method. Proc Natl Acad Sci USA. 1997;94:6048–53.
Demidov ON, Timofeev O, Lwin HNY, Kek C, Appella E, Bulavin DV. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis within the mouse gut. Cell Stem Cell. 2007;1:180–90.
Zhu YH, Zhang CW, Lu L, Demidov ON, Solar L, Yang L, et al. Wip1 regulates the technology of latest neural cells within the grownup olfactory bulb by means of p53-dependent cell cycle management. Stem Cells. 2009;27:1433–42.
Chen Z, Yi W, Morita Y, Wang H, Cong Y, Liu J-P, et al. Wip1 deficiency impairs haematopoietic stem cell perform by way of p53 and mTORC1 pathways. Nat Commun. 2015;6:6808.
Lu X, Nannenga B, Donehower L. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 2005;19:1162–74.
Lindqvist A, de Bruijn M, Macurek L, Bras A, Mensinga A, Bruinsma W. Wip1 confers G2 checkpoint restoration competence by counteracting p53-dependent transcriptional repression. EMBO J. 2009;28:3196–206.
Lee J-S, Lee M-O, Moon B-H, Shim SH, Fornace AJ, Cha H-J. Senescent development arrest in mesenchymal stem cells is bypassed by Wip1-mediated downregulation of intrinsic stress signaling pathways. Stem Cells. 2009;27:1963–75.
Lu X, Ma O, Nguyen T-A, Jones SN, Oren M, Donehower LA. The Wip1 phosphatase acts as a gatekeeper within the p53-Mdm2 autoregulatory loop. Most cancers Cell. 2007;12:342–54.
Martinikova AS, Burocziova M, Stoyanov M, Macurek L. Truncated PPM1D prevents apoptosis within the murine thymus and promotes ionizing radiation-induced lymphoma. Cells. 2020;9:9.
Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, et al. The position of the MKK6//p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene. 2006;26:2502–6.
Schito M, Demidov O, Saito S, Ashwell J, Appella E. Wip1 phosphatase-deficient mice exhibit faulty T cell maturation attributable to sustained p53 activation. J Immunol. 2006;176:4818–25.
Solar L, Li H, Luo H, Zhang L, Hu X, Yang T, et al. Phosphatase Wip1 is crucial for the maturation and homeostasis of medullary thymic epithelial cells in mice. J Immunol. 2013;191:3210–20.
Liu G, Hu X, Solar B, Yang T, Shi J, Zhang L, et al. Phosphatase Wip1 negatively regulates neutrophil growth by means of p38 MAPK-STAT1. Blood. 2013;121:519–29.
Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis by means of p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway. Nat Genet. 2004;36:343–50.
Shreeram S, Hee W, Demidov O, Kek C, Yamaguchi H, Fornace A. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med. 2006;203:2793–9.
Bulavin DV, Demidov ON, Saito SI, Kauraniemi P, Phillips C, Amundson SA, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor exercise. Nat Genet. 2002;31:210.
Zhang L, Hsu JI, Goodell MA. PPM1D in Stable and Hematologic Malignancies: buddy and foe? Mol Most cancers Res. 2022;20:1365–78.
Kleiblova P, Shaltiel IA, Benada J, Sevčík J, Pecháčková S, Pohlreich P, et al. Achieve-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint. J Cell Biol. 2013;201:511–21.
Burocziova M, Burdova Ok, Martinikova AS, Kasparek P, Kleiblova P, Danielsen SA, et al. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes development of APC-deficient tumors within the mouse colon. Cell Dying Dis. 2019;10:818.
Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23:700–13.e6.
Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, et al. PPM1D truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood. 2018;132:1095.
Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations related to clonal hematopoietic enlargement and malignancies. Nat Med. 2014;20:1472.
Kar SP, Quiros PM, Gu M, Jiang T, Mitchell J, Langdon R, et al. Genome-wide analyses of 200,453 people yield new insights into the causes and penalties of clonal hematopoiesis. Nat Genet. 2022;54:1155–66.
Warren JT, Hyperlink DC. Clonal hematopoiesis and threat for hematologic malignancy. Blood. 2020;136:1599–605.
Pich O, Reyes-Salazar I, Gonzalez-Perez A, Lopez-Bigas N. Discovering the drivers of clonal hematopoiesis. Nat Commun. 2022;13:4267.
Yura Y, Miura-Yura E, Katanasaka Y, Min KD, Chavkin N, Polizio AH, et al. The most cancers therapy-related clonal hematopoiesis driver Gene Ppm1d promotes irritation and non-ischemic coronary heart failure in mice. Circ Res. 2021;129:684–98.
Fuster JJ. Clonal hematopoiesis and heart problems in most cancers sufferers and survivors. Thromb Res. 2022;213:S107–s12.
Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, et al. Somatic mosaic mutations in PPM1D and TP53 within the blood of girls with ovarian carcinoma. JAMA Oncol. 2016;2:370–2.
Zajkowicz A, Butkiewicz D, Drosik A, Giglok M, Suwiński R, Rusin M. Truncating mutations of PPM1D are present in blood DNA samples of lung most cancers sufferers. Br J Most cancers. 2015;112:1114–20.
Danek P, Kardosova M, Janeckova L, Karkoulia E, Vanickova Ok, Fabisik M, et al. β-Catenin-TCF/LEF signaling promotes steady-state and emergency granulopoiesis by way of G-CSF receptor upregulation. Blood. 2020;136:2574–87.
Hu Y, Smyth GK. ELDA: excessive limiting dilution evaluation for evaluating depleted and enriched populations in stem cell and different assays. J Immunol Strategies. 2009;347:70–8.
Liao Y, Smyth GK, Shi W. featureCounts: an environment friendly common objective program for assigning sequence reads to genomic options. Bioinforma (Oxf, Engl). 2014;30:923–30.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment evaluation: a knowledge-based strategy for deciphering genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
Bartha Á, Győrffy B. TNMplot.com: A Net Device for the Comparability of Gene Expression in Regular, Tumor and Metastatic Tissues. Int J Mol Sci. 2021;22:2622.
Andrysik Z, Sullivan KD, Kieft JS, Espinosa JM. PPM1D suppresses p53-dependent transactivation and cell dying by inhibiting the Built-in Stress Response. Nat Commun. 2022;13:7400.
Baumgartner C, Toifl S, Farlik M, Halbritter F, Scheicher R, Fischer I, et al. An ERK-dependent suggestions mechanism prevents hematopoietic stem cell exhaustion. Cell Stem Cell. 2018;22:879–92.e6.
Fernandes H, Moura J, Carvalho E. mTOR signaling as a regulator of hematopoietic stem cell destiny. Stem Cell Rev Rep. 2021;17:1312–22.
Wilson A, Murphy MJ, Oskarsson T, Kaloulis Ok, Bettess MD, Oser GM, et al. c-Myc controls the stability between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 2004;18:2747–63.
Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, et al. Satb1 regulates the self-renewal of hematopoietic stem cells by selling quiescence and repressing differentiation dedication. Nat Immunol. 2013;14:437–45.
McGill MA, Dho SE, Weinmaster G, McGlade CJ. Numb regulates post-endocytic trafficking and degradation of Notch1. J Biol Chem. 2009;284:26427–38.
McGill MA, McGlade CJ. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular area. J Biol Chem. 2003;278:23196–203.
Racioppi L, Lento W, Huang W, Arvai S, Doan PL, Harris JR, et al. Calcium/calmodulin-dependent kinase kinase 2 regulates hematopoietic stem and progenitor cell regeneration. Cell Dying Dis. 2017;8:e3076.
Tokumitsu H, Hatano N, Inuzuka H, Sueyoshi Y, Yokokura S, Ichimura T, et al. Phosphorylation of Numb household proteins. Attainable involvement of Ca2+/calmodulin-dependent protein kinases. J Biol Chem. 2005;280:35108–18.
Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, et al. CD99 is a therapeutic goal on illness stem cells in myeloid malignancies. Sci Transl Med. 2017;9:374.
Zhang N, Shen Y, Li H, Chen Y, Zhang P, Lou S, et al. The m6A reader IGF2BP3 promotes acute myeloid leukemia development by enhancing RCC2 stability. Exp Mol Med. 2022;54:194–205.
Tran TM, Philipp J, Bassi JS, Nibber N, Draper JM, Lin TL, et al. The RNA-binding protein IGF2BP3 is essential for MLL-AF4-mediated leukemogenesis. Leukemia. 2022;36:68–79.
Zhang B, Yang L, Wang X, Fu D. Identification of survival-related different splicing signatures in acute myeloid leukemia. Biosci Rep. 2021;41:7.
M Hosseini M, Lin H-Y, Dewson G, Vivier R, Agarwal A. Marcks is a essential downstream mediator of IL-1-Pushed AML development. Blood 2019;134:2679.
Menezes AC, Jones R, Shrestha A, Nicholson R, Leckenby A, Azevedo A, et al. Elevated expression of RUNX3 inhibits regular human myeloid growth. Leukemia 2022;36:1769–80.
Chang P, Chen S, Chang X, Zhu J, Tang Q, Ma L. EXTL3 may function a possible biomarker of prognosis and immunotherapy for prostate most cancers and its potential mechanisms. Eur J Med Res. 2022;27:115.
Sinnakannu JR, Lee KL, Cheng S, Li J, Yu M, Tan SP, et al. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in continual myeloid leukemia. Leukemia. 2020;34:1787–98.
Okuda H, Miyamoto R, Takahashi S, Kawamura T, Ichikawa J, Harada I, et al. RNA-binding proteins of KHDRBS and IGF2BP households management the oncogenic exercise of MLL-AF4. Nat Commun. 2022;13:6688.
Du M, Peng Y, Li Y, Solar W, Zhu H, Wu J, et al. MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma. Cell Dying Discov. 2022;8:53.
Li W, Deng X, Chen J. RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in most cancers. Semin Most cancers Biol. 2022;86:664–77.
Ruark E, Snape Ok, Humburg P, Loveday C, Bajrami I, Brough R, et al. Mosaic PPM1D mutations are related to predisposition to breast and ovarian most cancers. Nature. 2013;493:406–10.
Khadka P, Reitman ZJ, Lu S, Buchan G, Gionet G, Dubois F, et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022;13:604.
Dubois F, Shapira O, Greenwald NF, Zack T, Wala J, Tsai JW, et al. Structural variants form driver combos and outcomes in pediatric high-grade glioma. Nat Most cancers. 2022;3:994–1011.
Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet. 2008;9:115–28.
Lee-Six H, Øbro NF, Shepherd MS, Grossmann S, Dawson Ok, Belmonte M, et al. Inhabitants dynamics of regular human blood inferred from somatic mutations. Nature 2018;561:473–8.
Pietras EM, Warr MR, Passegué E. Cell cycle regulation in hematopoietic stem cells. J Cell Biol. 2011;195:709–20.
Wirtz-Peitz F, Nishimura T, Knoblich JA. Linking cell cycle to uneven division: Aurora-A phosphorylates the Par complicated to manage Numb localization. Cell .2008;135:161–73.
Clausse V, Fang Y, Tao D, Tagad HD, Solar H, Wang Y, et al. Discovery of novel small-molecule scaffolds for the inhibition and activation of WIP1 Phosphatase from a rapidfire mass spectrometry high-throughput display screen. ACS Pharmacol Transl Sci. 2022;5:993–1006.
Miller PG, Sathappa M, Moroco JA. Allosteric inhibition of PPM1D serine/threonine phosphatase by way of an altered conformational state. Nat Commun. 2022;13:3778.
